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Summary 
Nerve growth factor (NGF) induces neurite outgrowth and promotes survival of 
embryonic sensory and sympathetic neurons. TRKA, a receptor tyrosine kinase cloned 
from a human colon cancer was later found to be expressed in the nervous system and 
phosphorylated in response to NGF. Somatic rearrangement(s) of the TRKA gene (also 
designated NTRK1) are responsible for formation of some oncogenes. Genetic defects in 
TRKA are responsible for a human disorder, congenital insensitivity to pain with 
anhidrosis (CIPA). We report here isolation and characterization of the TRKA gene 
which spans at least 23 kb and is split into 17 exons. Exon sizes range from 18 to 394 bp 
and intron sizes range from 170 bp to at least 3.3 kb. Sizes and boundaries of the exons 
were determined, and all the splice donor and acceptor sites conformed to the GT/AG 
rule. Approximately 1.2 kb of the 5’-flanking regions was sequenced, and putative 
regulatory elements were identified. These results will be useful for studies on the 
developmental and biological regulation of the TRKA gene and for further 
characterization of mutations in CIPA patients as well as elucidation of mechanisms 
responsible for rearrangement(s) observed in human tumors. 
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Cell survival, growth and differentiation in nervous systems are mediated by numerous 
growth factors, including neurotrophic factors (neurotrophins). Nerve growth factor (NGF), 
the first neurotrophic factor to be discovered, supports the survival of sympathetic ganglion 
neurons and subpopulations of mainly nociceptive sensory neurons in dorsal root ganglia 
derived from the neural crest as well as ascending cholinergic neurons of the basal forebrain 
(Levi-Montalcini, 1987; Thoenen and Barde, 1980). The TRKA (also named NTRK1) was 
isolated from a colon carcinoma as a potential new member of the tyrosine kinase gene 
family (Martin-Zanca et al., 1986) and was later found to be expressed in the nervous 
system (Martin-Zanca et al., 1990). TRKA is a receptor tyrosine kinase and is 
phosphorylated in response to NGF (Kaplan et al., 1991; Klein et al., 1991). 
Congenital insensitivity to pain with anhidrosis (CIPA; McKusick: 256800, also known 
as congenital sensory neuropathy with anhidrosis, hereditary sensory and autonomic 
neuropathy type IV) is an autosomal-recessive genetic disease characterized by recurrent 
episodes of unexplained fever, anhidrosis (absence of sweating) and absence of reaction to 
noxious stimuli, self-mutilating behavior, and mental retardation (Swanson, 1963; Dyck, 
1984; McKusick, 1994). Recently, we have reported that the gene responsible for CIPA is 
TRKA, suggesting that the NGF-TRKA system plays a crucial role in development and 
function of the nociceptive reception as well as establishment of thermoregulation via 
sweating systems in humans (Indo et al., 1996).  
The TRKA gene is located on the q arm of chromosome 1 (Miozzo et al., 1990; Morris et 
al., 1991). The TRKA -derived oncogenes are also detected in human breast tumor cells 
(Kozma et al., 1988) or in papillary thyroid carcinoma (Butti et al., 1995; Greco et al., 1995). 
These oncogenes are activated by somatic rearrangements juxtaposing their tyrosine kinase 
domain to the 5’-end sequences derived from unrelated loci and producing chimeric 
oncogenes whose products display a constitutive and ectopic tyrosine kinase activity. 
Breakpoints producing some oncogenes often involve a specific region of the TRKA gene 
and part of its sequence has been described (Greco et al., 1993). However, the exact location 
of this region in the whole TRKA gene is unknown, as structure of this gene has not been 
documented. 
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We have now defined the structural and genomic organization of TRKA. This knowledge 
will be useful for studies in developmental and biological regulation of the TRKA gene and 
further characterization of mutation(s) in CIPA patients and as well as elucidation of 
mechanisms responsible for rearrangement(s) of TRKA in human tumors. 
A phage library constructed from human leukocytes (Clontech, Palo Alto, CA) was 
screened to obtain DNA fragments from the TRKA gene. We used a human TRKA cDNA 
(pLM6) (Martin-Zanca et al., 1989) as a radioactively labeled probe and isolated two clones 
(T6 and T11), covering the entire genomic region of TRKA, as shown in Fig. 1. We 
previously characterized the TRKA gene encoding the intracellular domain (Indo et al., 1996). 
In the present study, all the exon/intron splice junctions were determined by comparing the 
human TRKA genomic sequences with the human TRKA cDNA sequences. Size of introns 
was estimated by the sequence of restriction fragments or polymerase chain reaction. The 
human TRKA gene divided into 17 exons ranged in size from 18 bases (exon 9) to 394 bases 
(exon 17), and 16 introns ranged in size from 170 bases (intron 9) to at least 3.3 kb (intron 1). 
The entire human TRKA gene was estimated to span at least 23 kb. The sequences of exon-
intron boundaries are presented in Table 1. All of the splice donor and acceptor sites 
conformed to the GT/AG rule for nucleotides immediately flanking the exon border (Shapiro 
and Senapathy, 1987). 
A single transmembrane domain divides the TRKA protein into an extracellular and an 
intracellular domain (Snider, 1994; Barbacid, 1995). The extracellular domain is important 
for specific NGF binding and includes a signal peptide, three tandem leucine-rich motifs 
flanked by two cysteine clusters, and two immunoglobulin-like domains (or motifs). The 
intracellular domain includes a juxtamembrane region, a tyrosine kinase domain, and a very 
short carboxy-terminal tail (Barbacid, 1995). We found a general correlation between the 
genomic organization of the TRKA gene and the functional organization of TRKA protein. 
Exon 1 contains the signal peptide and the first cysteine cluster. Three leucine-rich motifs are 
encoded by exons 2, 3 and 4, respectively. This suggests that simple duplication can account 
for the variable numbers of the motif. Exon 5 contains the second cysteine cluster. The first 
immunoglobulin-like motif is encoded by exons 6 and 7, while the second immunoglobulin-
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like motif is encoded by the single exon 8. Thus, the splice sites of the TRKA gene encoding 
the extracellular domain separate the functional domains so that each domain is encoded by 
separate exons. Exon 9 is a small (18-bp) one incorporated into mRNA by alternative 
splicing and six amino acid residues encoded by this exon are present in the extracellular 
domain of the neuronal-specific TRKA receptor (Barker et al., 1993). The transmembrane 
domain is encoded by exons 10 and 11 and the intracellular domain of TRKA is encoded by 
exons 11-17. The juxtamembrane domain is encoded by exons 11 and 12. The domain 
contains an IXNPXpY motif where p indicates phosphorylation at Tyr-490 residue of the 
activated TRKA (Dikic et al., 1995). This motif is encoded by exon 12 and is recognized by 
an Shc adaptor protein required for activation of the Ras-MAPK pathway (Obermeier et al., 
1994; Stephens et al., 1994). The tyrosine kinase domain which is phosphorylated in 
response to NGF and is critical for the intercellular signaling is encoded by exons 13-17. A 
consensus sequence motif YXXM which interacts with phosphatidylinositol-3’ kinase, is 
located at the end of the kinase catalytic domain (Tyr-751 residue in TRKA) (Obermeier et 
al., 1993a; Soltoff et al., 1992) and encoded by exon 17. The short carboxy-terminal tail of 
15 amino acids is also encoded by exon 17 and includes a conserved Tyr residue (Tyr-785 in 
TRKA) which is responsible for binding of phospholipase Cγ (Obermeier et al., 1993b; Loeb 
et al., 1994). Thus, the functional domains or motifs are generally encoded by different 
exons, except for exons 10 and 11 which contain a small portion of the transmembrane 
region and a portion of the juxtamembrane region, respectively.  
In addition, there were discrepancies between the nucleotide sequences in exons 7 and 8 
of the genomic clone (T6) and those noted in the cDNA (Martin-Zanca et al., 1989). A single 
base substitution of T-871 to G in exon 7 and substitutions of dinucleotide CG (983 and 984) 
to GC in exon 8 changed codons as follows: Leu-263 to Val and Ser-300 to Cys, respectively. 
We also found these two substitutions in cDNAs from two normal controls and four CIPA 
subjects (data not shown). These amino acid changes were located in the immunoglobulin-
like motifs 1 and 2, respectively. In rat TRKA cDNA, two amino acids corresponding to these 
residues are also Val and Cys, respectively (Meakin et al., 1992). It is noteworthy because 
this immunoglobulin-like motif-2 is the structural element that determines the interaction of 
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neurotrophins with their receptors (Urfer et al., 1995). If our data are accurate, two Cys 
residues should be conserved in the second immunoglobulin-like motif of all human TRK 
family members as in the first immunoglobulin-like motif (Nakagawara et al., 1995). 
The nucleotide sequence of 1226 bp upstream from the base number 1 of the TRKA 
cDNA (Martin-Zanca, et al., 1989) is shown in Fig. 2a. A consensus CAAT or TATA 
elements were not present upstream of the putative region for transcription initiation. To 
determine regulatory sites in the TRKA gene, we used a computer program “TFSEARCH” 
based on a database, “TRANSFAC”, which compiled eukaryotic cis-acting regulatory DNA 
elements and trans-acting factors (Wingender, 1994). Sequences from vertebrates were 
selected on the threshold of 95.0. Sequences similar to the binding site for several 
transcription factors located between -420 and -990. Sequences homologous to the binding 
site for the following proteins were seen in this region: c-Rel /NF-κB (Kunsch et al., 1992; 
Baeuerle and Henkel, 1994; Schmidt et al., 1996) at position -898, AP-2 (Mitchell et al., 
1991; Faisst and Meyer, 1992) at position -852, CdxA (Margalit et al., 1993; Frumkin et al., 
1993) at position -809, CCAAT displacement protein (CDP-CR) (Neufeld et al., 1992; 
Harada et al., 1995) at position -767, and heat shock transcription factor (HSF) at position -
429 (both directions) (Kroeger and Morimoto, 1994). Determination of the precise putative 
promoter sites in transcriptional regulation of the TRKA gene is the subject of ongoing study. 
The nucleotide sequence of the 3’ exon region of the gene is shown in Fig. 2b. The site of the 
polyadenylation signal was inferred from the cDNA. A noncanonical polyadenylation signal 
was present 21 bases upstream of the polyadenine tail. 
Oncogenic rearrangements often involve the same region of the TRKA gene, resulting in 
the same junction. Our study indicates that the region frequently involved in the 
rearrangements is located in exons 8 through 12 of the TRKA. The structural and genomic 
organization of the whole human TRKA gene will provide a basis for elucidation of 
mechanisms responsible for such rearrangement(s). In addition, we found a microsatellite 
region (GT or CA repeat) located in intron 12. The nucleotide sequence flanking this locus 
was reported (Greco et al., 1993) and discussed (Butti et al., 1995). Position of this locus 
(AFMa127wh9) and data on the heterozygosity were described (Dib et al., 1996).  
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Clinically, CIPA is a serious illness that might be fatal in the first years of life if the 
hyperpyrexia is not properly overcome. In older children, osteomyelitis and bone and/or joint 
deformities demand surgical procedures sometimes involving extensive amputations (Dyck, 
1984; McKusick, 1994). To data, three different mutations in four families have been 
identified. A deletion-, a splice- and a missense-mutations all in the region encoding the 
tyrosine kinase domain were detected in these families. The present study revealed that a 
single base deletion and missense mutations are located in exon 14 of this gene. Splice 
mutation is located in the 5’-splice donor site of intron 15. This study will facilitate analyses 
of CIPA mutations in other regions of TRKA. Identification of such mutations will further 
genetic diagnoses of this painless but serious disease. 
 
 Acknowledgements 
We thank L.F. Parada for providing the pLM6 plasmid and M. Ohara for assistance with 
the manuscript. This work was funded in part by a Grant-in-Aid for Scientific Research (C) 
from the Ministry of Education, Science, Sports and Culture of Japan and the Research Grant 
(8A-7) for Nervous and Mental Disorders from the Ministry of Health and Welfare of Japan. 
  
 7
References 
Baeuerle PA, Henkel T (1994): Function and activation of NF-κB in the immune system. 
Annu Rev Immunol 12: 141-179 
Barbacid M (1995): Structural and functional properties of the TRK family of neurotrophin 
receptors. Ann N Y Acad Sci 766: 442-458 
Barker PA, Lomen HC, Gensch EM, Meakin SO, Glass DJ, Shooter EM (1993): Tissue-
specific alternative splicing generates two isoforms of the trkA receptor. J Biol Chem 
268: 15150-15157 
Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA (1995): A 
sequence analysis of the genomic regions involved in the rearrangements between TPM3 
and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 
28: 15-24 
Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, 
Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J (1996): A comprehensive 
genetic map of the human genome based on 5,264 microsatellites. Nature 380: 152-154 
Dikic I, Batzer AG, Blaikie P, Obermeier A, Ullrich A, Schlessinger J, Margolis B (1995): 
Shc binding to nerve growth factor receptor is mediated by the phosphotyrosine 
interaction domain. J Biol Chem 270: 15125-15129 
Dyck PJ (1984): Neuronal atrophy and degeneration predominantly affecting sensory and 
autonomic neurons. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds). Peripheral 
neuropathy. W. B. Saunders Company, Philadelphia. pp 1557-1599 
Faisst S, Meyer S (1992): Compilation of vertebrate-encoded transcription factors. Nucleic 
Acids Res 20: 23-26 
Frumkin A, Haffner R, Shapira E, Tarcic N, Gruenbaum Y, Fainsod A (1993): The chicken CdxA 
homeobox gene and axial positioning during gastrulation. Development 118: 553-562 
Greco A, Mariani C, Miranda C, Pagliardini S, Pierotti MA (1993): Characterization of the 
NTRK1 genomic region involved in chromosomal rearrangements generating TRK 
oncogenes. Genomics 18: 397-400 
 8
Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, Pierotti MA (1995): The 
DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on 
chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol 15: 6118-
6127 
Harada R, Berube G, Tamplin OJ, Denis LC, Nepveu A (1995): DNA-binding specificity of 
the cut repeats from the human cut-like protein. Mol Cell Biol 15: 129-140 
Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H, Tonoki H, 
Awaya Y, Matsuda I (1996): Mutations in the TRKA/NGF receptor gene in patients with 
congenital insensitivity to pain with anhidrosis. Nature Genet 13: 485-488 
Kaplan DR, Hempstead BL, Martin ZD, Chao MV, Parada LF (1991): The trk proto-
oncogene product: a signal transducing receptor for nerve growth factor. Science 252: 
554-558 
Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M (1991): The trk proto-oncogene 
encodes a receptor for nerve growth factor. Cell 65: 189-197 
Kozma SC, Redmond SM, Fu XC, Saurer SM, Groner B, Hynes NE (1988): Activation of 
the receptor kinase domain of the trk oncogene by recombination with two different 
cellular sequences. EMBO J 7: 147-154 
Kroeger PE, Morimoto RI (1994): Selection of new HSF1 and HSF2 DNA-binding sites 
reveals difference in trimer cooperativity. Mol Cell Biol 14: 7592-7603 
Kunsch C, Ruben SM, Rosen CA (1992): Selection of optimal κB/Rel DNA-binding motifs: 
interaction of both subunits of NF-κB with DNA is required for transcriptional activation. 
Mol Cell Biol 12: 4412-4421 
Levi-Montalcini R (1987): The nerve growth factor: thirty-five years later. EMBO J 6: 1145-
1154 
Loeb DM, Stephens RM, Copeland T, Kaplan DR, Greene LA (1994): A Trk nerve growth 
factor (NGF) receptor point mutation affecting interaction with phospholipase C-γ 1 
abolishes NGF-promoted peripherin induction but not neurite outgrowth. J Biol Chem 
269: 8901-8910 
 9
Margalit Y, Yarus S, Shapira E, Gruenbaum Y, Fainsod A (1993): Isolation and 
characterization of target sequences of the chicken CdxA homeobox gene. Nucleic Acids 
Res 21: 4915-4922 
Martin-Zanca D, Hughes SH, Barbacid M (1986): A human oncogene formed by the fusion 
of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319: 743-748 
Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M (1989): Molecular and 
biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 9: 24-33 
Martin-Zanca D, Barbacid M, Parada LF (1990): Expression of the trk proto-oncogene is 
restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse 
development. Genes Dev 4: 683-694 
McKusick VA (1994): Mendelian inheritance in man. The Johns Hopkins University Press, 
Baltimore 
Meakin SO, Suter U, Drinkwater CC, Welcher AA, Shooter EM (1992): The rat trk 
protooncogene product exhibits properties characteristic of the slow nerve growth factor 
receptor. Proc Natl Acad Sci USA 89: 2374-2378 
Miozzo M, Pierotti MA, Sozzi G, Radice P, Bongarzone I, Spurr NK, Della PG (1990): 
Human TRK proto-oncogene maps to chromosome 1q32-q41. Oncogene 5: 1411-1414 
Mitchell PJ, Timmons PM, Hebert JM, Rigby PW, Tjian R (1991): Transcription factor AP-2 
is expressed in neural crest cell lineages during mouse embryogenesis. Genes Dev 5: 105-
119 
Morris CM, Hao QL, Heisterkamp N, Fitzgerald PH, Groffen J (1991): Localization of the 
TRK proto-oncogene to human chromosome bands 1q23-1q24. Oncogene 6: 1093-1095 
Nakagawara A, Liu XG, Ikegaki N, White PS, Yamashiro DJ, Nycum LM, Biegel JA, 
Brodeur GM (1995): Cloning and chromosomal localization of the human TRK-B 
tyrosine kinase receptor gene (NTRK2). Genomics 25: 538-546 
Neufeld EJ, Skalnik DG, Lievens PM, Orkin SH (1992): Human CCAAT displacement 
protein is homologous to the Drosophila homeoprotein, cut. Nature Genetics 1: 50-55 
 10
Obermeier A, Lammers R, Wiesmuller KH, Jung G, Schlessinger J, Ullrich A (1993a): 
Identification of Trk binding sites for SHC and phosphatidylinositol 3'-kinase and 
formation of a multimeric signaling complex. J Biol Chem 268: 22963-22966 
Obermeier A, Halfter H, Wiesmuller KH, Jung G, Schlessinger J, Ullrich A (1993b): 
Tyrosine 785 is a major determinant of Trk-substrate interaction. EMBO J 12: 933-941 
Obermeier A, Bradshaw RA, Seedorf K, Choidas A, Schlessinger J, Ullrich A (1994): 
Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk 
binding sites for SHC and PLC γ. EMBO J 13: 1585-1590 
Schmidt UR, Memet S, Lilienbaum A, Feuillard J, Raphael M, Israel A (1996): NF-κB 
activity in transgenic mice: developmental regulation and tissue specificity. Development 
122: 2117-2128 
Shapiro MB, Senapathy P (1987): RNA splice junctions of different classes of eukaryotes: 
sequence statistics and functional implications in gene expression. Nucleic Acids Res 15: 
7155-7174 
Snider WD (1994): Functions of the neurotrophins during nervous system development: 
what the knockouts are teaching us. Cell 77: 627-638 
Soltoff SP, Rabin SL, Cantley LC, Kaplan DR (1992): Nerve growth factor promotes the 
activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase. 
J Biol Chem 267: 17472-7 
Stephens RM, Loeb DM, Copeland TD, Pawson T, Greene LA, Kaplan DR (1994): Trk 
receptors use redundant signal transduction pathways involving SHC and PLC-γ 1 to 
mediate NGF responses. Neuron 12: 691-705 
Swanson AG (1963): Congenital insensitivity to pain with anhidrosis. Arch Neurol 8: 299-306 
Thoenen H, Barde Y-A (1980): Physiology of nerve growth factor. Physiol Rev 60: 1284-1335 
Urfer R, Tsoulfas P, O'Connell L, Shelton DL, Parada LF, Presta LG (1995): An 
immunoglobulin-like domain determines the specificity of neurotrophin receptors. 
EMBO J 14: 2795-2805 
Wingender E (1994): Recognition of regulatory regions in genomic sequences. J Biotechnol 
35: 273-280 
 11
Figures 
Fig. 1. Physical map of the human TRKA gene. 
 
 
 
Fig. 1. Physical map of the human TRKA gene.  
The structure of the gene is shown by a thick line. Exons 1-17 are shown as vertical lines and 
numbered. Below the gene structure, the genomic DNA fragments from the phage clones are 
shown by dotted lines. BamHI and SacI sites are shown above. 
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Fig. 2. Nucleotide sequences of the 5’ and 3’ regions of the human TRKA gene. 
 
 
 
Fig. 2. Nucleotide sequences of the 5’ and 3’ regions of the human TRKA gene.  
(a) Nucleotide sequence of the 5’ region of the gene.  
The sequence is numbered according to Martin-Zanca et al (Martin-Zanca et al., 1989), 
starting from guanine at base number 1 of the cDNA. Sequences with a horizontal arrow 
indicate the putative region resembling binding sites for specific transcription factors. The 
directions of the sequence are indicated by the directions of the arrows. The translation start 
codon ATG is underlined.  
(b) Nucleotide sequences of the 3’ region of the gene.  
The termination codon, TAG, is marked (***). The sequence is numbered starting from 
thymidine of the termination codon. A vertical arrowhead indicates the poly(A) addition site. 
The noncanonical poly(A) addition signal is boxed. 
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Table 1  
Exon-Intron Organization of the human TRKA gene 
 Size cDNA  Size     
Exon (bp) positiona Intron (kb) Exon  Intron Exon 
  
 1 
 
 
296 
    
   1-296 
  
 1 
 
3.3 
 
GAG CT 
Glu Leu 
 
gtgagtgtccggcgggcggt 
 
..... cccatccgctctccccacag
 
  C TAC 
Leu Tyr 
 2  75 297-371  2 0.3 AAC CT 
Asn Leu 
gtgagggaaacggggactgt ..... cctcctgcacccctccccag   C ACC 
Leu Thr 
 3  72 372-443  3 2.1 CGC CT 
Arg Leu 
gtgagtgtggccagtgctgg ..... ctgtgtctccacgcccgcag   G AAT 
Leu Asn 
 4  69 444-512  4 1.2 GAA CT 
Glu Leu 
gtgagtgggggcgcttccag ..... gtgtcccccatgccccccag   G GTC 
Leu Val 
 5 146 513-658  5 0.3 TGT G 
Cys Gly 
gtaggtgccgggtgagggag ..... cgggcgtcctgggtggccag  GT GTG 
Gly GTG 
 6 143 659-801  6 2.3 GTG ATG 
Val Met 
gtgagaagaccttcgctggc ..... ccctctctttcctgatctag AAA TCT 
Lys Ser 
 7 133 802-934  7 2.1 TCC T 
Ser Phe 
gtgagtctcagtggcagctc ..... ttgctctttctggcccacag  TC CCG 
Phe Pro 
 8 327  935-1261  8 0.4 CCT G 
Pro Val 
gtgcgagggccatcctgaac ..... tctcctccctcctgctgcag  TC TCC 
Val Ser 
 9b  18 -  9 0.2 GTG G 
Val Asp 
gtgagtagcccaaggtggag ..... cctgccctgtgtccctacag  AC ACT 
Asp Thr 
10  56 1262-1317 10 0.3 TTT GGG 
Phe Gly 
gtgagataggaagtagaagc ..... ctacccctgtcccccaccag GTC TCG 
Val Ser 
11 103 1318-1420 11 0.5 AAC C 
Asn Arg 
gtgagtcggggctgcagaggg ..... cggctgtgtctcctctctag  GC CCG 
Arg Pro 
12 147 1421-1567 12 0.4 GCC T 
Ala Cys 
gtgaggggctatgctgggtc ..... gaccctgcaagccccctcag  GT GTT 
Cys Val 
13 131 1568-1698 13 0.2 GTC AAG 
Val Lys 
gtgagaccctgccccggggg ..... tccctgccgcttccatccag GCA CTG 
Ala Leu 
14 173 1699-1871 14 2.5 CTC CG 
Leu Arg 
gtaccagcacctggcctcag ..... tctccttttcttgttcacag   A TCC 
Arg Ser 
15 241 1872-2112 15 0.7 TAC CGT 
Tyr Arg 
gtaagggtcctttgtcccca ..... gcagtgtccgcccgtggcag GTG GGA 
Val Gly 
16 159 2113-2271 16 1.2 ACG GAG 
Thr Glu 
gtcagccccggcccatggtc ..... tgtctctccggtggccccag GCA ATC 
Ala Ile 
17 394 2272-2665   CTT G 
 
   
a Numbered according to Martin-Zanca et al. (1986). 
b A small exon incorporated into mRNA of neural tissues by alternative splicing (Barker et al., 1993). 
